Our company, ARNA Genomics, was considered by the expert jury of the contest and was chosen as one of the few who entered the final of the AstraZeneca Startup Challenge 2018 project.
AstraZeneca Startup Challenge – competition for the best innovative project and solution in the early and late stages in the field of oncology, cardiovascular diseases, metabolism and kidneys, respiratory and autoimmune diseases. The contest is supported by the Skolkovo Foundation and the international biopharmaceutical company AstraZeneca.
Why did our company get into the contest and was recognized as one of the best and most worthy? Because we are developing a unique test for determining breast cancer, and according to laboratory tests, its accuracy is 95%. The test itself is based on the fluid biopsy method.
We look at free-circulating DNA in the blood plasma and determine the presence of cancer of any stage and any type. A DNA cell after disintegration that has entered the bloodstream is called free-circulating or ss-DNA. Our development allows detecting in the blood samples the presence of identified 6 oncospecific genes. Their increased amount in the obtained sample is associated with the oncological process that has begun in the patient’s breast tissue.
The ARNA technology platform allows the development of tests for many cancers: lung, liver, pancreas, colon, ovarian and prostate cancer. Currently, we are actively working on new tests, which will soon be introduced into the practice of early detection of cancer.